alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 380.2 [Reserved]
<PAGE>

                                                                    Exhibit 32.1


                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

         In connection with the quarterly report on Form 10-Q of Metal
Management, Inc. (the "Corporation") for the period ended September 30, 2006
(the "Report"), I, Daniel W. Dienst, the Chairman of the Board, Chief Executive
Officer and President of the Corporation, and I, Robert C. Larry, Executive Vice
President, Finance, Chief Financial Officer, Treasurer and Secretary of the
Corporation, each certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         (1) to my knowledge, the Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Corporation.



  /s/ Daniel W. Dienst
--------------------------------------------
Daniel W. Dienst
Chairman of the Board, Chief
Executive Officer and President
November 2, 2006

  /s/ Robert C. Larry
--------------------------------------------
Robert C. Larry
Executive Vice President, Finance, Chief
Financial Officer, Treasurer and Secretary
November 2, 2006

         A signed original of this written statement required by Section 906 has
been provided to the Corporation and will be retained by the Corporation and
furnished to the Securities and Exchange Commission or its staff upon request.
Record of Discussion 

Docket No. F AA-20 12-0603 Directorate Identifier: 2012-NE-17-AD 

With whom outside the FAA has this action been discussed (i.e., Design Approval Holder, 

manufacturer, ATA, NBAA, RAA, AOPA, ALPA, GAMA, etc)? 

ORGANIZATION PERSON CONTACTED DATE TOPICS DISCUSSED 

James Meade 8/27112 Other. List below. 

Other/Additional Information: Responded to email comment to FR. 

9
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access to publicationsin the archive is available through GPO's suite of cataloging and locatorservices, including the Catalog of U.S. Government Publications (CGP). Archived copies of publications are retrieved in the event that publicationsare no longer available from the original publishing agency site. 
**Title:****Report**
 
SuDoc Number:Y 3.AD 9/12:1/

Item Number:1049-L-01 (online)
CGP systemNumber:000603752
 
1982 | 1983 | 1985 | 1986 | 1989 | 1991 | 1993 | 2004 | 2005
 
March 4, 2020
<PAGE>   1

                                                                 EXHIBIT 10.9(b)

                         1993 DIRECTOR STOCK OPTION PLAN

                                 AMENDMENT NO. 3


       The 1993 Director Stock Option Plan (the "Plan") is amended effective as
of June 29, 2000, as follows:

       Section 3 of the Director Plan is amended to read in its entirety as
follows:

       Stock Subject to the Plan. Subject to the provisions of Section 10 of the
Plan, the maximum aggregate number of Shares which may be optioned and sold
under the Plan is 100,000 Shares(1) (the "Pool") of Common Stock. The Shares may
be authorized but unissued or reacquired Common Stock.

       If an Option should expire or become unexercisable for any reason without
having been exercised in full, the unpurchased Shares which were subject thereto
shall, unless the Plan shall have been terminated, become available for future
grant under the Plan.




--------
(1) Includes increase of 40,000 Shares on June 29, 2000.
#### § 338.8 Compilation of loan data in register format.

FDIC-supervised institutions and other lenders required to file a Home Mortgage Disclosure Act loan/application register (LAR) with the Federal Deposit Insurance Corporation shall collect, record and report such LAR in accordance with Regulation C of the Bureau of Consumer Financial Protection (12 CFR part 1003).
Exhibit 10.2




                             Promissory Note
$ 75,000.00 USD               Temple, Texas                    Date Mar.21, 2001


FOR VALUE RECEIVED, after date, without grace, in the manner, on the dates, and
in the amounts so herein stipulated, the Undersigned, Communicate Now.com Inc.

PROMISE TO PAY TO THE ORDER OF : David Hancock, At Temple, Texas in Bell County 

              THE SUM OF SEVENTY FIVE THOUSAND DOLLARS ($75,000.00)


In lawful money of the United States of America, which shall be legal tender, in
payments of all debts and dues, public and private at the time of payment, and
to pay interest thereon from the date until maturity at the rate of 6.0% per
annum, payable as stipulated herein.


THIS NOTE IS DUE AND PAYABLE AS FOLLOWS TO WIT:

SEVENTY FIVE THOUSAND DOLLARS ($75,000.00) principal due in one year (on or
before March 21, 2002). Interest of 4,500.00 per year payable in monthly amounts
of $375.00 on the 21st of each month

IT IS AGREED that time is of the essence of this agreement, and that in the
event of default in the payment of any installment of principal or interest when
due, the holder of this note may declare the entirety of the evidenced herby due
and payable without notice, and failure to exercise said option shall not
constitute a waiver on part of the holder of the right to exercise the same at
any other time.

IN THE EVENT of default in the making of any payment herein provided, either or
principal or interest, or in the event the entirety of said note evidenced
hereby is declared due, interest shall accrue at the rate of 10.0% per annum
from such time.

THE UNDERSIGNED HEREBY AGREES to pay all expenses incurred, including an
additional 10.0% on the amount of principal and interest hereof as attorney's
fees, all of which shall become part of the principal hereof, if this note is
placed in the hands of an attorney for collection, or if collected by suite or
through any probate, bankruptcy or other legal proceedings,

EACH MAKER, SURETY and endorser waives demand, grace, notice, presentment for
payment, and protest and agrees and consents that this note an the liens
securing its payment, may be renewed, and the time of payment extended without
notice, and without releasing any of the parties.


                             CommunicateNow.Com Inc.

                            David Hancock, President
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Member Conflict SEP.                    

*Date:*                         November 3, 2009.                    

*Time:*                         11 a.m. to 2 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Embassy Suites Hotel, 4300 Military Road, Washington, DC 20015.                    

*Contact Person:*                         Shanta Rajaram, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC9529, Bethesda, MD 20852, (301) 435-6033,                         *rajarams@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: October 6, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-24599 Filed 10-9-09; 8:45 am]

BILLING CODE 4140-01-P
Exhibit 10.2

 



 

BALTIC TRADING LIMITED

299 PARK AVENUE, 12TH FLOOR

NEW YORK, NY 10171

646-443-8550

 

April 30, 2015

 

Mr. John C. Wobensmith

Baltic Trading Limited

299 Park Avenue, 12th Floor

New York, NY 10171

 

Dear John:

 

The purpose of this letter is to confirm our understanding regarding that agreement between you and Baltic Trading Limited (the “Company”) dated December 19, 2013, as amended prior to the date hereof (the “Agreement”).  It is hereby agreed as follows:

 

1.  You hereby waive, and the Company also hereby waives, all rights under the Agreement, which waiver will not become effective until immediately prior to the consummation of the transactions (the “Closing”) contemplated by the Agreement and Plan of Merger, dated as of April 7, 2015, between the Company and Genco Shipping & Trading Limited.  Immediately prior to the Closing, the Agreement will be terminated and will be of no further force and effect.  If the Closing does not occur, then the Agreement will not be terminated and the waiver contained in the first sentence of this paragraph will be null and void.  Notwithstanding anything in this paragraph to the contrary, neither the waiver contained herein, nor the termination of the Agreement, will have any effect on any equity awards (such as restricted stock) granted to you prior to the date hereof, including under Sections 5(c) and 5(e) of the Agreement, and such equity awards will continue to be governed by the applicable award agreements and plan documents.

 

2.  This letter contains the entire understanding between the parties on the subjects covered here and supersedes all prior agreements, arrangements and understandings, whether written or oral, regarding the subjects covered here. This letter may not be changed, nor may any of their provisions be waived, orally, but may only be changed in writing signed by both parties.

 

3.  You agree and acknowledge that the parties hereto have been provided with the opportunity to consult with counsel regarding the provisions of this letter.

 

[Signature page follows.]

 











 

	
Very   truly yours,
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
BALTIC   TRADING LIMITED
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   John Wobensmith
    	
 
    	
 
    
	
 
    	
Name:   John Wobensmith
    	
 
    	
 
    
	
 
    	
Title:   President and Chief Financial Officer
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
ACCEPTED   AND AGREED TO:
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
/s/   John Wobensmith
    	
 
    	
 
    
	
 
    	
John   Wobensmith
    	
 
    	
 
    
	
 
    	
Date:   4/30/15
§ 367.17 Duration of suspensions and exclusions. ( a ) *Suspensions.* ( 1 ) Suspensions shall be for a temporary period pending the completion of an investigation or other legal or exclusion proceedings.
( 2 ) If legal or administrative proceedings are not initiated within 12 months after the date of the suspension notice, the suspension shall be terminated unless a representative of the Department of Justice requests its extension in writing. In such cases, the suspension may be extended for an additional six months. In no event may a suspension be imposed for more than 18 months, unless such proceedings have been initiated within that period.
( 3 ) FDIC shall notify the Department of Justice of an impending termination of a suspension at least 30 days before the 12-month period expires to give the Department of Justice an opportunity to request an extension.
( 4 ) The time limitations for suspension in this section may be waived by the affected contractor.
( b ) *Exclusions.* ( 1 ) Exclusions shall be for a period commensurate with the seriousness of the cause(s) after due consideration of mitigating evidence presented by the contractor.
( 2 ) If a suspension precedes an exclusion, the suspension period shall be considered in determining the exclusion period.
( 3 ) Exclusion for causes other than the mandatory bars in 12 CFR 366.4(a) generally should not exceed three years, but where circumstances warrant, a longer period of exclusion may be imposed.
( 4 ) The Ethics Counselor may extend an existing exclusion for an additional period if the Ethics Counselor determines that an extension is necessary to protect the integrity of the FDIC contracting program and the public interest. However, an exclusion may not be extended solely on the basis of the facts and circumstances upon which the initial exclusion action was based. The standards and procedures in this part shall be applied in any proceeding to extend an exclusion.
Exhibig
      10.3




**AMENDMENT
      TO EMPLOYMENT AGREEMENT**




**THIS
      AMENDMENT** (this
“Amendment”) is dated August 8, 2006, between THERAGENICS CORPORATION, a
      Delaware corporation (the “Company”), and M. CHRISTINE JACOBS, an individual
      resident of Georgia (the “Executive”).




**INTRODUCTION**




The
      Company and the Executive entered into that certain Employment Agreement dated
      April 13, 2000 (the “Employment Agreement”). The parties hereto now desire to
      amend the Employment Agreement to delete the provision providing for perquisites
      up to $40,000 annually and agree that such deletion shall not allow the
      Executive to resign for “Good Reason.”




**NOW,
      THEREFORE** ,
      and in
      consideration of the Executive’s continued employment with the Company, the
      Company and the Executive hereby mutually agree that, effective immediately
      following the payment made to the Executive pursuant to Section 5(c) in March
      2006, the Employment Agreement is amended as follows:




1.  By
      deleting in its entirety the existing content of Section 5(c) and replacing
      therefor the term “[Reserved.]”




2.  By
      adding
      the following language immediately before the period at the end of the first
      sentence of Section 17(s)(iii):




“;
      provided, however, that the amendment to this Agreement to delete the $40,000
      benefit in Section 5(c) shall not be deemed to constitute ‘Good
      Reason’.”




Except
      as
      specifically amended hereby, the Employment Agreement shall remain in full
      force
      and effect as prior to this Amendment.




**IN
      WITNESS WHEREOF** ,
      the
      Company and the Executive have each executed and delivered this Amendment as
      of
      the date first shown above.




**THE COMPANY:**
            
            **THE
              EXECUTIVE:**THERAGENICS CORPORATION
            
            /s/ M. Christine
              JacobsM. Christine JacobsBy:
/s/
              Francis J. TaralloTitle: Chief
              Financial Officer and Treasurer
§ 308.34 Hearing subpoenas. ( a ) *Issuance.* ( 1 ) Upon application of a party showing general relevance and reasonableness of scope of the testimony or other evidence sought, the ALJ may issue a subpoena or a subpoena *duces tecum* requiring the attendance of a witness at the hearing or the production of documentary or physical evidence at the hearing. The application for a hearing subpoena must also contain a proposed subpoena specifying the attendance of a witness or the production of evidence from any state, territory, or possession of the United States, the District of Columbia, or as otherwise provided by law at any designated place where the hearing is being conducted. The party making the application must serve a copy of the application and the proposed subpoena on every other party.
( 2 ) A party may apply for a hearing subpoena at any time before the commencement of a hearing. During a hearing, a party may make an application for a subpoena orally on the record before the ALJ.
( 3 ) The ALJ will promptly issue any hearing subpoena requested pursuant to this section. If the ALJ determines that the application does not set forth a valid basis for the issuance of the subpoena, or that any of its terms are unreasonable, oppressive, excessive in scope, or unduly burdensome, the ALJ may refuse to issue the subpoena or may issue it in a modified form upon any conditions consistent with this subpart. Upon issuance by the ALJ, the party making the application must serve the subpoena on the person named in the subpoena and on each party.
( b ) *Motion to quash or modify.* ( 1 ) Any person to whom a hearing subpoena is directed or any party may file a motion to quash or modify the subpoena, accompanied by a statement of the basis for quashing or modifying the subpoena. The movant must serve the motion on each party and on the person named in the subpoena. Any party may respond to the motion within ten days of service of the motion.
( 2 ) Any motion to quash or modify a hearing subpoena must be filed prior to the time specified in the subpoena for compliance but not more than ten days after the date of service of the subpoena upon the movant.
( c ) *Enforcing subpoenas.* If a subpoenaed person fails to comply with any subpoena issued pursuant to this section or any order of the ALJ which directs compliance with all or any portion of a document subpoena, the subpoenaing party or any other aggrieved party may seek enforcement of the subpoena pursuant to § 308.26(c).
June 22, 2000


Richard J. Kirby
C/O Directrix, Inc.
236 West 26th Street, Suite 12W
New York, New York 10001

Re: Employment Agreement effective as of March 15, 1999

Dear Mr. Kirby:

We refer to the Employment  Agreement between Directrix,  Inc. and you effective
as of March 15, 1999 ("Employment  Agreement").  All terms not otherwise defined
herein shall have the same meaning as in the Employment Agreement.

         1.  Salary Reduction.  At our  request,  you have agreed to a temporary
reduction in  your Base  Salary from $202,584 to $180,000 effective with the pay
period  beginning June 24, 2000  and through  the end of  our fiscal  year ended
March 31, 2001.

         2.  Option  Issuance.   In  consideration  of  your  agreement  to  the
reduction  in your  Base Salary provided for above,  we will grant you an option
("Option")  to acquire  5,000 shares  of  Directrix  Common  Stock  in  the form
attached.   The Option provides for an exercise price of $4.00 per share and the
Option is fully vested.

If the foregoing  correctly reflects you agreement with the matters provided for
herein, please sign below.

We appreciate your support of Directrix.

Sincerely,
DIRECTRIX, INC.




By:_________________________________
   J. Roger Faherty,
   Chairman & CEO


AGREED TO:



____________________________________
Richard J. Kirby
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF HEALTHDYNE TECHNOLOGIES, INC. AND
SUBSIDIARIES FOR THE PERIOD ENDED DECEMBER 31, 1996, AND IS QUALIFIED IN ITS
ENTIRETY BE REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           3,041
<SECURITIES>                                         0
<RECEIVABLES>                                   37,357
<ALLOWANCES>                                     1,193
<INVENTORY>                                     18,593
<CURRENT-ASSETS>                                61,617
<PP&E>                                          20,294
<DEPRECIATION>                                  11,000
<TOTAL-ASSETS>                                  98,078
<CURRENT-LIABILITIES>                           24,730
<BONDS>                                         29,078
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           126
<OTHER-SE>                                      44,144
<TOTAL-LIABILITY-AND-EQUITY>                    98,078
<SALES>                                        118,318
<TOTAL-REVENUES>                               118,318
<CGS>                                           70,981
<TOTAL-COSTS>                                   70,981
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,398
<INCOME-PRETAX>                                  9,530
<INCOME-TAX>                                     3,805
<INCOME-CONTINUING>                              5,725
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,725
<EPS-PRIMARY>                                      .44
<EPS-DILUTED>                                        0


</TABLE>
§ 380.50 Determination of secured claims. ( a ) In the case of a claim against a covered financial company that is secured by any property of the covered financial company, the Corporation as receiver shall determine the amount of the claim, whether the claimant's security interest is legally enforceable and perfected, the priority of the claimant's security interest, and the fair market value of the property that is subject to the security interest. The Corporation as receiver may treat the portion of the claim which exceeds an amount equal to the fair market value of such property as an unsecured claim.
( b ) The fair market value of any property of a covered financial company that secures a claim shall be determined in light of the purpose of the valuation and of the proposed disposition or use of such property and at the time of such proposed disposition or use.
( c ) The Corporation as receiver may recover from any property of a covered financial company that secures a claim the reasonable and necessary costs and expenses of preserving or disposing of such property to the extent of any benefit to the claimant, including the payment of all ad valorem property taxes with respect to such property.
( d ) To the extent that a claim is secured by property of a covered financial company and the value of such property, after any recovery under paragraph (c) of this section, is greater than the amount of such claim, there shall be allowed to the claimant a secured claim for interest on such claim and any reasonable fees, costs, or charges provided for under the agreement or State statute under which the claim arose to the extent of the value of such property.